|Kythera Biopharmaceuticals Inc -- USA Stock|| |
0.12 0.00 0.00%
Chief Medical Officer
Dr. Frederick Beddingfield III M.D. Ph.D. is Chief Medical Officer of the Company. Dr. Beddingfield joined KYTHERA from Allergan Inc. a multispecialty health care company where he joined in 2003 and has served as Vice President and Global Therapeutic Area Head of Dermatology and Aesthetics at Allergan since August 2005 as well as Chief Medical Officer of Allergan Medical from December 2008 through August 2010. Since 2001 Dr. Beddingfield has also served as an Assistant Clinical Professor of Medicine Division of Dermatology at the David Geffen School of Medicine at UCLA
Age: 49 Executive Since 2013 Ph.D
Beddingfield received his M.D. from the University of North Carolina at Chapel Hill, with honors, and a Bachelor of Arts in Psychology from North Carolina State University in Raleigh, N.C. In addition, Dr. Beddingfield holds a Ph.D. in Policy Analysis from the RAND Graduate School of Policy Studies.
The company has return on total asset (ROA)
of (40.45) %
which means that it has lost $40.45 on every $100 spent on asset. This is way below average.
The company currently holds 24.65 M in liabilities with Debt to Equity (D/E) ratio of 0.17 which may suggest the company is not taking enough advantage from borrowing. Kythera Biopharmaceuticals Inc has Current Ratio of 7.97 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
KYTHERA Biopharmaceuticals, Inc., a clinicalstage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription solutions for the aesthetic medicine market in the United States and internationally. Kythera Biopharmaceuticals Inc (KYTH) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 212 people. Kythera Biopharmaceutica is listed under Pharmaceutical Products category by Fama And French industry classification.